Upon EGFR inhibitor-targeted therapy, a standard first-line treatment for NSCLC, IQGAP1 is significantly increased in microvascular endothelial cells, which decreases cell–cell adhesion, increases endothelial cell permeability, and eventually contributes to treatment-induced vascular adverse events, such as purpuric drug eruptions [148]. This evidence concerns the gene IQGAP1 and non-small cell lung carcinoma.